(0.18%) 5 258.13 points
(0.15%) 39 819 points
(-0.07%) 16 389 points
(2.03%) $83.00
(1.63%) $1.746
(1.23%) $2 240.00
(0.90%) $24.98
(1.29%) $921.40
(0.39%) $0.927
(0.75%) $10.85
(0.14%) $0.792
(0.14%) $92.57
-10.00% $ 0.000900
Live Chart Being Loaded With Signals
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders...
Stats | |
---|---|
Today's Volume | 1.70M |
Average Volume | 15.07M |
Market Cap | 328 877 |
EPS | $-0.00153 ( 2023-11-17 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0400 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2020-09-30 | Dickason David | Buy | 2 000 000 | Common Stock Options (to purchase shares of Common Stock) |
2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Common Stock |
2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Warrants (to purchase Common Stock) |
2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Common Stock |
2020-09-30 | Jones Timothy L. | Buy | 4 409 063 | Warrants (to purchase Common Stock) |
INSIDER POWER |
---|
0.00 |
Last 99 transactions |
Buy: 326 429 999 | Sell: 11 508 564 |
RespireRx Pharmaceuticals Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
RespireRx Pharmaceuticals Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $0 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.00150 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.00400 |
Q1 | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.00390 |
Financial Reports:
No articles found.
RespireRx Pharmaceuticals
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators